IMR Press / JOMH / Volume 18 / Issue 2 / DOI: 10.31083/jomh.2021.133
Open Access Communication
A single centre pilot experience with 18F-JK-PSMA-7 PET-CT in the staging of prostate cancer
Show Less
1 Department of Oncoradiology, Petz Aladár Hospital, 9024 Győr, Hungary
2 Department of Pathology, Petz Aladár Hospital, 9024 Győr, Hungary
3 Department of Urology, Petz Aladár Hospital, 9024 Győr, Hungary
*Correspondence: (Kullmann Tamás)
J. Mens. Health 2022, 18(2), 45;
Submitted: 1 September 2021 | Accepted: 23 September 2021 | Published: 10 February 2022
(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Background: The sensitivity and specificity of bone scintigraphy and thoraco-abdominopelvic CT scans traditionally used for the staging of prostate cancer don’t meet clinical requirements. In 2020 18F-JK-PSMA-7 positron emission tomography-computed tomography (PET-CT) became available in our country for routine clinical diagnostics. Methods: As part of our self-assessment, we retrospectively analysed the results of 24 PSMA PET-CTs realised for our patients up to 31 December 2020. Results: The indication of the examination was biochemical recurrence after radical prostatectomy (prostate specific antigen (PSA) >0.2 ng/mL) for 16 patients and primary staging (PSA range: 5.2–70 ng/mL) for 8 patients. Biochemical recurrence was related to local relapse in 2 cases, regional lymph node involvement in 5 cases, oligo- and multi-metastatic spread in 1 and 3 cases respectively. 5 patients had no detectable lesion. Patients with PSA <1 ng/mL showed no extrapelvic enhancement. At primary staging 3 patients presented distant metastases. There was no correlation between PSA level and disease extent. In total PSMA PET-CT results changed the treatment strategy for 7 patients. Conclusions: 18F-JK-PSMA-7 PET-CT is a useful diagnostic tool. The examination can lead to change the treatment decision at primary staging as well as at biochemical recurrence. The results of this pilot study may support the strategy that patients with biochemical recurrence following radical prostatectomy receive salvage radiotherapy to the prostate bed and the pelvic lymphatic regions without any imaging examination when PSA <1 ng/mL.

Prostate cancer
Biochemical relapse
Therapy optimisation
Back to top